Introduction
Diabetes mellitus is an important risk factor for the development of coronary artery disease (CAD) and is associated with poor clinical outcomes. 1 While patients with diabetes and less extensive coronary disease may be initially treated with optimal medical therapy alone, those with multivessel coronary disease (MVD) have been shown to derive a benefit from coronary revascularization with coronary artery bypass graft (CABG) mainly through a reduction in myocardial infarction (MI) rates. 2 Coronary artery bypass graft and PCI are currently acceptable options for performing revascularization in subjects with diabetes and multivessel CAD. 3 Previous data comparing CABG with PCI in the era of balloon angioplasty and bare metal stents showed that, in subjects with diabetes, CABG was associated with a significantly lower 5-year mortality rate. 4 The introduction of drug eluting stents (DES) was followed by improvement in outcomes for PCI, especially in subsets associated with high rates of restenosis like the diabetic subset. 5 The future revascularization evaluation in patients with diabetes mellitus: optimal management of multivessel disease (FREEDOM) trial is the largest randomized trial that compared PCI using DES with CABG in patients with diabetes and multivessel CAD. 6 In that trial, CABG had a significantly lower rate of the safety composite primary endpoint of all-cause death, MI or stroke at a median follow-up of 3.8 years. The difference in the composite endpoint was driven by lower rates of both MI and all-cause mortality, with the stroke rate being higher with CABG as compared to PCI. These results led to CABG being recommended overall as the first choice revascularization strategy for patients with diabetes and multivessel CAD. 3 Interestingly, differently from other trials in multivessel coronary disease, the FREEDOM trial did not detect interaction with treatment effect of anatomic complexity measured by the SYNTAX score. 6, 7 Nevertheless, according to the most recent European
Guidelines on myocardial revascularization, it is unclear if in FREEDOM the SYNTAX scores were assessed in a blinded fashion by an independent angiographic core laboratory as was done in other studies. 3 Such careful analysis is of paramount importance to guarantee reproducibility and accuracy of score calculations.
In the present study, we perform a patient-level pooled analysis of three large randomized controlled trials (the SYNTAX, PRECOMBAT, and BEST trials), all of which had independent corelab assessment of SYNTAX scores, with the following objectives: (i) To assess major cardiovascular outcomes stratifying the population according to anatomic SYNTAX score terciles; (ii) To assess the performance of the SYNTAX score II in patients with and without diabetes using the PRECOMBAT and BEST trials as external validation cohorts.
7-9

Methods
The Synergy Between PCI With TAXUS and Cardiac Surgery (SYNTAX) multicentre, randomized controlled trial compared PCI with the use of paclitaxel eluting stents with CABG in 1800 patients with left-main and/ or multivessel CAD in centres in Europe and the United States. 7 The PRECOMBAT trial (bypass surgery vs. angioplasty using sirolimus-eluting stent in patients with left main coronary artery disease) was a randomized trial conducted at 13 sites in South Korea that included 600 patients with documented unprotected left-main disease. 8 The BEST (randomized comparison of coronary artery bypass surgery and everolimus-eluting stent implantation in the treatment of patients with multivessel coronary artery disease) multicentre, randomized controlled trial compared PCI using everolimus eluting stents with CABG for treatment of patients with multivessel CAD without left-main stem involvement in centres in South Korea, China, Malaysia, and Thailand. In the present study, we performed a merging of the individual patient-level data of the three trials. 9 
Study population
All patients with diabetes and multivessel CAD and/or left-main involvement randomized in the SYNTAX, PRECOMBAT, and BEST trials were included. Treatment for diabetes included diet only, oral medication and/ or insulin therapy. Of note, in previous SYNTAX trial reports on patients with diabetes, those treated with diet only (n = 59) were excluded.
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Study endpoints and definitions
The primary endpoint of the present study was the composite of all-cause death, non-fatal MI, or stroke. revascularization and major adverse cardiovascular and cerebral events (MACCE), a composite of all-cause death, stroke, MI and all-cause revascularization. All endpoints were defined using the original trials' definitions and are described in detail elsewhere. In all studies independent clinical events committees blinded to group allocation adjudicated all events.
SYNTAX score II
The SYNTAX score II is a tool developed for the customized selection of the revascularization strategy (i.e. PCI or CABG) associated with the lowest all-cause mortality rate in patients with multivessel disease. 11 It is a Cox regression derived mortality prediction model that accounts for coronary anatomy (anatomic SYNTAX score and presence of left-main disease) and demographic and clinical factors (age, gender, ejection fraction, creatinine clearance, presence of peripheral vascular disease, and chronic obstructive pulmonary disease [COPD]). 11, 12 These factors showed independent association with mortality and interaction with the revascularization strategy in the landmark SYNTAX trial. 11 The SYNTAX score II does not include diabetes status, since it was not an independent predictor of all-cause mortality in the SYNTAX trial and it didn't show interaction with CABG/PCI. 11 In the present study we assess the performance of the SYNTAX score II in patients with and without diabetes. variable. A Forest plot is used to illustrate the primary endpoint in different subgroups with interaction for treatment effect assessed. All analyses follow the intention-to-treat principle.
Statistical considerations
The performance of SYNTAX score II prediction model in patients with and without diabetes was assessed with calibration plots (with calibration slopes and intercepts) and c-indexes. Two-sided P-values <0.05 were considered statistically significant. SPSS software v21 (IBM corporation) was used for all analyses.
Results
Study population
The SYNTAX, PRECOMBAT, and BEST trials combined randomized 3280 patients to undergo either CABG or PCI. Overall, 1068 (32.6%) had a diagnosis for diabetes mellitus, of which 537 were randomized to PCI and 531 to CABG. Baseline characteristics were well balanced between the study arms ( Table 1) . Overall, mean age was 64.7 ± 8.9 years, 71.7% were male and 22.4% required insulin treatment. Additionally, 366 (34.3%) patients had left-main disease and the remainder (n = 702, 65.7%) had three-vessel disease (3-VD) ( Table 1) . SYNTAX score was available in 1053 (98.6%) cases and averaged 27.5 ± 10.0, with 32.8% (n = 350) being in the low (0-22) tercile, 38.3% (n = 409) in the intermediate (23-32) tercile and 27.5% (n = 294) in the high (> _33) tercile ( Table 2) .
Regarding procedural characteristics, in the PCI arm, an average of 4.0 ± 2.1 stents per patient were used with a total stent length of 86.7 ± 45.4 mm per patient. First generation drugeluting stents (DES) were used in 67.2% of cases and newer generation everolimus eluting stents in the remainder 32.8%. In the CABG arm, a total of 2.9 ± 0.8 conduits (1.7 ± 0.9 arterial conduits) per patients were used. Left internal mammary artery (LIMA) was used in 90.8% and off-pump surgery in 40.3% of patients ( Table 1) . A significant difference in the use of LIMA grafts was observed between the SYNTAX trial (84.9%) and the Korean trials altogether (97.3%), with a P-value <0.001. The number of arterial grafts was also lower in SYNTAX (mean 1.4 ± 0.7) compared to the Korean trials (mean 2.0 ± 0.9). Table 3 describes the medical treatment at discharge and last follow-up in both arms. The use of guideline directed medical therapy was significantly more frequent in the PCI arm at both time points.
Clinical outcomes
Overall, mean and median follow-up were 5.2 ± 1.0 and 5.0 (5.0, 6.0) years, respectively. The primary endpoint of death, MI or stroke occurred in 94 (17.5%) patients in the PCI arm and 77 (14.5%) patients in the CABG arm (HR 1.19, 95% CI 0.88-1.6; P = 0.27). The rates of all-cause death (HR 1.33, 95% CI 0.93-1.89; P = 0.12), cardiac death (HR 1.48, 95% CI 0.94-2.31; P = 0.09) and stroke (HR 0.57, 95% CI 0.26-1.25, P = 0.16) were not statistically different between the two treatment arms. A trend towards a higher MI rate associated with PCI was observed (HR 1.79, 95% CI 0.99-3.24; P = 0.053). PCI was associated with higher rates of all-cause revascularization (HR 2.7, 95% CI 1.92-3.8, P < 0.001) and MACCE (HR 1.72, 95% CI 1.36-2.18; P < 0.001), a composite of all-cause death, stroke, MI or revascularization ( Table 2) .
Outcomes according to SYNTAX score terciles
The rates of the primary endpoint in the PCI and CABG arms were similar for patients with low (scores 0-22) (14.5% vs. 11.3%; HR 1.25, 95% CI 0.69-2.25; P = 0.46) and intermediate (score 23-32) SYNTAX scores (15.7% vs. 18.2%; HR 0.82, 95% CI 0.51-1.32; P = 0.42); respectively ( Table 2) . Percutaneous coronary intervention was associated with a significantly higher rate of the primary endpoint of death, MI or stroke only in the subset of high (> _33) SYNTAX score (24.5% vs. 13.2%, HR 1.92, 95% CI 1.11-3.32; P = 0.02) ( Table 2 ).
The population was further grouped into low-intermediate (< _32) SYNTAX scores and high (> _33) SYNTAX scores. Figure 1 depicts Kaplan-Meier curves of the primary endpoint (A, B) , of all-cause death (C, D) and cardiac death (E, F) according to the SYNTAX score group. In patients with low-intermediate (< _32) SYNTAX scores, the curves of the CABG and PCI for all three outcomes ( Figure 1A : death/ MI/stroke; C: all-cause death, and E: cardiac death) run superimposed up to 5 years of follow-up with no difference in outcomes between the groups. In patients in the high SYNTAX score (> _33) subset, the curves start to diverge in the early follow-up phase and PCI is associated with significantly higher rates of all three outcomes as compared with CABG ( Figures 1B, D, and F) .
Left-main and three-vessel disease cohort
As an exploratory analysis we assessed the primary outcome in the left-main and 3-VD cohorts. In patients in the 3-VD cohort, death/MI/stroke rates were consistent with the overall population with similar outcomes between PCI and CABG in patients with low-intermediate (< _32) SYNTAX scores (14.9% vs. 13.5%, respectively; P = 0.79) and better results with CABG in patients with high (> _33) SYNTAX scores (30.0% vs. 7.6%, respectively; P < 0.001) (Figure 2 difference in the rates of the primary endpoint was observed between the two treatment strategies regardless of the SYNTAX score, with event rates numerically higher in the CABG arm in both low-intermediate and high SYNTAX score groups.
Subgroup analysis
The overall results for the primary endpoint are consistent across different subgroups (Figure 3 ). No interaction with treatment effect was observed with gender, insulin treatment, presence of COPD, peripheral vascular disease, left-ventricular dysfunction or renal failure. Results were also consistent in all three trials included in this pooled analysis. Significant P-values for interaction were observed for SYNTAX score groups (P = 0.049) and left main/3-VD cohorts (P = 0.044). Accordingly, the safety benefit of CABG was statistically significant in patients without left-main disease and in patients with high SYNTAX scores (> _33) ( Figure 3) .
SYNTAX score II model performance
Using the PRECOMBAT and BEST trials populations as external validation cohorts we observed that the SYNTAX score II model showed good calibration for mortality prediction in both patients with (Intercept = 0.04; P < 0.001, and slope = 1.04; P < 0.001) and without diabetes (Intercept = 0.03; P < 0.001, and slope = 1.05; P < 0.001). The score showed moderate discrimination ability, similar in patients with and without diabetes (c-indexes 0.68; P < 0.001 and 0.67; P < 0.001]; respectively) ( Figure 4 ).
Discussion
The findings of the present study are consistent with the fact that differences in 5 years outcomes following PCI and CABG for patients with multivessel CAD and diabetes seem to be significantly impacted by anatomic complexity as measured by the anatomic SYNTAX score. Our data show that, while in patients with low-intermediate (< _32) SYNTAX scores, PCI, and CABG showed superimposed Kaplan-Meier curves of all-cause death, cardiac death and the composite of death, MI and stroke throughout the entire 5 years of follow-up, in patients with high (> _33) SYNTAX scores, PCI had significantly higher rates of these outcomes. Importantly, differences were observed in the use of LIMA grafts in patients with diabetes between the trials, being significantly lower in the SYNTAX trial, which accounted for 47.8% of the pooled population. Additionally, the use of guideline directed medical therapy was significantly more frequent in the PCI arm both at hospital discharge and at final follow-up (Table 3) . Therefore, these results should be interpreted taking into account that in a large part of the population CABG was performed with less use of LIMA, that medical therapy was less frequently used in CABG treated patients, and that first generation stents were used in the majority of the PCI treated subjects. Additionally, we observed that the SYNTAX score II mortality prediction model showed similar performance in terms of good calibration and moderate discrimination ability in patients with diabetes when compared with those without.
Diabetes mellitus association with poor outcomes in patients with coronary disease is well documented. 13 As compared with medical treatment, coronary revascularization is associated with a reduction in major adverse cardiovascular events in selected patients with more extensive disease. 2 Although, diabetes is implicated in poor results after PCI due to higher restenosis rates and need for repeated revascularization procedures, it is also associated with poor results after CABG if compared with absence of diabetes. 1, 14, 15 The advantage of CABG over PCI in patients with multivessel and/ or left-main disease and diabetes related to less need for repeat revascularization procedures has been established. 1, 10 On the other hand, the safety difference in terms of all-cause death, MI or stroke between the two treatment strategies in these patients is less clear. Furthermore, the existence of subgroups in which PCI and CABG are equally safe at long-term follow up has not been fully explored.
The FREEDOM trial is the only large randomized trial to compare CABG with PCI using DES in patients with multivessel coronary disease and diabetes. The trial showed that, overall, CABG was safer than PCI due to lower rates of MI and death, despite a higher rate of stroke. 6 Although these results are conflicting with the results of the SYNTAX trial, FREEDOM was powered for that finding while Figure 3 Forest plot for the primary endpoint across different subgroups.
Diabetes and SYNTAX score in multivessel coronary disease SYNTAX was not. However, some questions were still left unanswered after the results of the FREEDOM were known. First, the lack of impact of coronary anatomic complexity measured by the SYNTAX score in the overall trial results is also conflicting with previous evidence. 7, [16] [17] [18] The SYNTAX score has consistently shown to be predictive of outcomes and to interact with treatment effect in patients with multivessel disease, being recommended by multinational practice guidelines as a tool to help decision making regarding the selection of the best revascularization strategy in patients with multivessel disease. 3, 19 In fact, in the SYNTAX trial, when the SYNTAX score was included in a multivariable model, diabetes was no longer associated with mortality.
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The uncertainty about an independent corelab assessment of the SYNTAX scores in the FREEDOM trial, as pointed out in the most recent European guidelines for coronary revascularization, might have played a role in that finding. 3 The score became operational when FREEDOM was still ongoing and it is not mentioned in the study protocol. The discrepancy between site heart team and corelab assessments of the score was demonstrated previously in the SYNTAX trial and recently in the EXCEL trial, in which a quarter of patients deemed at low-intermediate anatomical complexity by the site had actually high SYNTAX score by corelab assessment. 7, 20 In the present study, the SYNTAX score had a significant interaction with treatment effect (Figure 2) . In the 759 patients with lowintermediate SYNTAX scores, the Kaplan-Meier curves for all-cause death, cardiac death and the composite of death, MI and stroke for both PCI and CABG run completely superimposed throughout the entire 5 years of follow-up. On the other hand, in patients with high SYNTAX scores, the curves start to diverge very early with a significant benefit of CABG seen for all three outcomes (Figure 1) .
The second unanswered question after FREEDOM was the impact of left-main disease (LMD). While LMD was an exclusion criterion in FREEDOM, in our study it also had significant interaction with treatment effect (Figure 2 ). This might in part explain the differences between our results and FREEDOM's. In our analysis, the benefit of CABG over PCI for the safety primary endpoint was restricted to the 3-VD cohort with similar safety between the two treatments in patients with left-main disease (Figure 2) . Nevertheless, even in the 3-VD cohort, the rates of death/MI/stroke were similar between CABG and PCI in patients with low-intermediate SYNTAX scores with superimposed Kaplan-Meier curves up to 5 years of follow-up. Notably, these subgroup analyses are underpowered and should be interpreted as hypothesis generating only.
Performance SYNTAX II score
In the SYNTAX trial, diabetes did not relate to mortality independently from coronary anatomy and other factors. 11, 21 Furthermore, the non-independent increase in mortality existed in both the PCI and CABG arms and to a somewhat similar extent. 11 For these reasons, Diabetes was not included as a component of the SYNTAX score II, because the score provides a prediction of mortality following PCI and CABG based on factors with interaction for treatment effect and diabetes did not have interaction. In the present analysis, using the external validation cohort of patients from PRECOMBAT and BEST trials, we demonstrated that the SYNTAX score II performed similarly in both patients with and without diabetes. This reassures the lack of necessity of including diabetes in the score.
Study limitations
The present study has some limitations. First, the pooled analysis nature is subject to bias related to heterogeneity of the patients included from the different trials as well as the different performance in patients with diabetes of the different stents used in each trial. [7] [8] [9] Second, it is striking that in these three studies together, the event rates were much lower than those observed in the FREEDOM trial, despite the similar risk profile of both populations. Thus, due to this lower event rate in both arms, our study was still unpowered to detect a possible difference in the primary endpoint between CABG and PCI as well as a potential difference in overall mortality in favour of CABG. Nevertheless, the distribution of events in this long-term follow up, as depicted in the Kaplan-Meier curves, is reassuring for our findings.
Conclusions
In this large pooled population of patients with diabetes and left-main and/or three-vessel CAD, differences in 5-year outcomes following CABG and PCI for patients with diabetes and multivessel CAD were related to anatomic complexity as measured by the anatomic SYNTAX score. In patients with low-intermediate SYNTAX score (< _32), PCI should be considered as an alternative to CABG, while in patients with high SYNTAX scores (> _33), CABG is clearly safer than PCI. The SYNTAX score II showed good calibration and moderate discrimination ability regardless of diabetes status.
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